Pharmacokinetic profile of dexloxiglumide

Clinical Pharmacokinetics

Volumn 45, Issue 12, 2006, Pages 1177-1188

  Persiani, Stefano ^a   D'Amato, Massimo ^a   Jakate, Abhijeet ^b   Roy, Partha ^c   Wangsa, Julie ^d   Kapil, Ram ^b   Rovati, Lucio C ^a  

^a Rotta Research Laboratorium   (Italy)

^b FOREST RESEARCH INSTITUTE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d Forest Research Institute Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 DEACETYL NORGESTIMATE; CIMETIDINE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DEXLOXIGLUMIDE; DEXLOXIGLUMIDE CARBOXYLIC ACID; DICLOFENAC; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; FLUCONAZOLE; KETOCONAZOLE; NORGESTIMATE; O DEMETHYL DEXLOXIGLUMIDE;

CONSTIPATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FECES LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG URINE LEVEL; DYSPEPSIA; FECES ANALYSIS; FOOD DRUG INTERACTION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ABSORPTION; HUMAN; IRRITABLE COLON; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STOMACH FUNCTION DISORDER; URINARY EXCRETION;

ADMINISTRATION, ORAL; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; GASTROINTESTINAL DISEASES; HEPATIC INSUFFICIENCY; HUMANS; METABOLIC CLEARANCE RATE; PENTANOIC ACIDS; RECEPTOR, CHOLECYSTOKININ A;

EID: 33845438851     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645120-00003     Document Type: Review

References (20)

1. Drossman DA, Corazziari E, Talley NJ, et al. Rome II: functional gastrointestinal disorders. Diagnosis, pathophysiology and treatment: a multinational consensus. 2nd ed. McLean (VA): Degnon Associates, 2000
2. Shajan AS, D'Amato M, Beglinger C. CCK1 antagonists: are they ready for clinical use? Dig Dis 2006; 24: 1-13
3. Webber C, Stokes CA, Persiani S, et al. Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the rat. Eur J Drug Metab Pharmacokinet 2003; 28 (3): 201-12
4. Webber C, Stokes CA, Persiani S, et al. Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the dog. Eur J Drug Metab Pharmacokinet 2004; 29 (1): 15-23
5. CR 2017. The effects on selected hepatic enzymatic activities and related parameters in the rat following oral gavage administration for 14 days. Report No. RCL025/012210. Rottapharm SpA, 2001 Aug. (Data on file)
6. D'Amato M, Whorwell PJ, Thomson DG, et al. The CCK1 receptor antagonist dexloxiglumide is effective and safe in female patients with constipation predominant irritable bowel syndrome [abstract]. Am J Gastroenterol 2001; 96: S31
7. Brodie R, Peard A, Roth A, et al. Development and validation of a bioanalytical method for the determination of the cholecystokinin type-1 (CCK1) receptor antagonist dexloxiglumide in human plasma. J Chromatogr B 2003; 784: 91-100
8. Jakate AS, Roy P, Patel A, et al. Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide. Br J Clin Pharmacol 2005; 60 (5): 498-507
9. Webber C, Roth A, Persiani S, et al. Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects. Xenobiotica 2003; 33 (6): 625-41
10. Tolle-Sander S, Grill A, Joshi H, et al. Characterization of dexloxiglumide in vitro biopharmaceutical properties and active transport. J Pharm Sci 2003; 92 (10): 1968-80
11. Persiani S, D'Amato M, Makovec F, et al. Pharmacokinetics of dexloxiglumide after administration of single and repeated oral escalating doses in healthy young males. Int J Clin Pharmacol Ther 2002; 40 (5): 198-206
12. Roy P, Jakate A, Niamehr S, et al. Evaluation of intestinal absorption sites for dexloxiglumide, a novel selective cholecystokinin (CCK1) receptor antagonist, in healthy subjects [abstract]. 2004 AAPS Annual Meeting and Exposition; 2005 Nov 7-11; Baltimore (MD)
13. Roy P, Nolting A, Abramowitz W, et al. Effect of a high fat meal on the bioavailability of dexloxiglumide from tablet in healthy subjects [abstract]. 2003 AAPS Annual Meeting and Exposition; 2003 Oct 26-30; Salt Lake City (UT)
14. Forest Research Institute Inc. Study Dex-PK-05. A single oral dose pharmacokinetic study of dexloxiglumide in subjects with mild to severe hepatic impairment. Jersey City (NJ): Forest Research Institute Inc., 2004 May. (Data on file)
15. Forest Research Institute Inc. Study Dex-PK-10. The effect of steady state Cimetidine on the pharmacokinetics of dexloxiglumide in healthy young subjects. Jersey City (NJ): Forest Research Institute Inc., 2004 May. (Data on file)
16. Hall M, Persiani S, Cheung Y-L, et al. Interaction of dexloxiglumide, a cholecystokinin type-1 receptor antagonist, with human cytochromes P450. Biopharm Drug Dispos 2004; 25: 163-76
17. Dexloxiglumide (CR 2017), CR 3695, CR 3729. Comparative evaluation of affinity towards CCK1 receptors, by radio-receptor binding in rat pancreatic acini. Report RRL-CR 2017 03/72-03/84. Monza: Rottapharm SpA, 2003 Feb. (Data on file)
18. Roy P, Wangsa J, Patel A, et al. The single-dose pharmacokinetics of the novel CCK1 receptor antagonist, dexloxiglumide, are not influenced by age and gender. Int J Clin Pharmacol Ther 2005; 43 (9): 444-51
19. Forest Research Institute Inc. Study Dex-PK-07. A study of the pharmacokinetic interaction between single dose diclofenac and dexloxiglumide at steady state in healthy young subjects. Jersey City (NJ): Forest Research Institute Inc., 2003 Nov. (Data on file)
20. Roy P, Jakate AS, Patel A, et al. Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women. J Clin Pharmacol 2005; 45: 329-36